FDA: NTID and “HVNTID” [Design Issues]

posted by Helmut Homepage – Vienna, Austria, 2020-03-13 10:35 2a02:8388:6bc2:ce80:856f:1d4e:74d9:7171 – Posting: # 21265
Views: 744

Hi Pharma_88,

» » » Further, what is the BE limit for such drugs?
» »
» » It depends on \(\small{s_{wR}}\) observed in the study, i.e., reference-scaling is applied. Furthermore – irrespective of passing the scaled limits – the study has to pass 80.00–125.00% as well and the upper confidence limit of \(\small{\sigma_{wT}/\sigma_{wR}}\) has to be ≤2.5.
»
» its common for all NTI or its varies from drug to drug?

The former. Check the guidances I linked above. Maybe there are more, do your homework.

There are exceptions: “Highly variable narrrow therapeutic index drugs”. AFAIK:2×2×4 design, conventional ABE with 80.00–125.00%, upper CL of \(\small{\sigma_{wT}/\sigma_{wR}}\) ≤2.5.
Certain inclusion criteria to decrease risk of bleeding (prothrombin time and activated partial thromboplastin time within their normal ranges, creatinine clearance ≤50 mL/min).

Cheers,
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

Activity
 Admin contact
20,458 posts in 4,296 threads, 1,414 registered users;
online 7 (0 registered, 7 guests [including 3 identified bots]).
Forum time (Europe/Vienna): 20:43 CEST

Genius is that which forces
the inertia of humanity to learn.    Henri Bergson

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5